• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Letter Regarding "Radiotherapy Improves Survival in NSCLC After Oligoprogression on Immunotherapy: A Cohort Study".

作者信息

Kosaka Nanami, Kataoka Yuki

机构信息

Department of Respiratory Medicine, Hyogo Prefectural Amagasaki General Medical Center, Hyogo, Japan.

Department of Internal Medicine, Kyoto Min-Iren Asukai Hospital, Kyoto, Japan.

出版信息

JTO Clin Res Rep. 2024 Nov 1;6(1):100760. doi: 10.1016/j.jtocrr.2024.100760. eCollection 2025 Jan.

DOI:10.1016/j.jtocrr.2024.100760
PMID:39790370
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11712016/
Abstract
摘要

相似文献

1
Letter Regarding "Radiotherapy Improves Survival in NSCLC After Oligoprogression on Immunotherapy: A Cohort Study".关于“放射治疗改善免疫治疗后寡进展的非小细胞肺癌患者的生存率：一项队列研究”的信函
JTO Clin Res Rep. 2024 Nov 1;6(1):100760. doi: 10.1016/j.jtocrr.2024.100760. eCollection 2025 Jan.
2
Radiotherapy Improves Survival in NSCLC After Oligoprogression on Immunotherapy: A Cohort Study.放射治疗可提高免疫治疗后寡进展的非小细胞肺癌患者的生存率：一项队列研究。
JTO Clin Res Rep. 2024 May 30;5(10):100695. doi: 10.1016/j.jtocrr.2024.100695. eCollection 2024 Oct.
3
Progression Patterns, Treatment, and Prognosis Beyond Resistance of Responders to Immunotherapy in Advanced Non-Small Cell Lung Cancer.晚期非小细胞肺癌中免疫治疗应答者耐药后的进展模式、治疗及预后
Front Oncol. 2021 Mar 5;11:642883. doi: 10.3389/fonc.2021.642883. eCollection 2021.
4
Outcomes Analysis of Patients Receiving Local Ablative Therapy for Oligoprogressive Metastatic NSCLC Under First-Line Immunotherapy.一线免疫治疗下寡进展转移性 NSCLC 局部消融治疗患者的结局分析。
Clin Lung Cancer. 2024 Dec;25(8):e402-e410.e3. doi: 10.1016/j.cllc.2024.07.009. Epub 2024 Aug 8.
5
[Interest of focal radiotherapy in case of oligoprogression under immunotherapy in the treatment of metastatic non-small cell lung cancer].[免疫治疗期间寡进展的转移性非小细胞肺癌患者接受局部放疗的意义]
Bull Cancer. 2023 Dec;110(12):1234-1243. doi: 10.1016/j.bulcan.2023.09.006. Epub 2023 Oct 26.
6
The analysis of the efficacy and safety of stereotactic body radiotherapy with sequential immune checkpoint inhibitors in the management of oligoprogressive advanced non-small cell lung cancer.立体定向体部放疗联合序贯免疫检查点抑制剂治疗寡进展期晚期非小细胞肺癌的疗效和安全性分析
Transl Cancer Res. 2024 May 31;13(5):2408-2418. doi: 10.21037/tcr-23-2232. Epub 2024 May 7.
7
Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer.晚期非小细胞肺癌寡进展后立体定向体部放疗联合检查点抑制剂治疗
Transl Lung Cancer Res. 2021 Dec;10(12):4368-4379. doi: 10.21037/tlcr-21-682.
8
A Response Letter to Kosaka et al. Regarding Manuscript Titled: "Radiotherapy Improves Survival in Non-Small Cell Lung Cancer Following Oligoprogression on Immunotherapy: A Cohort Study".致小坂等人的回复信，关于题为《放射治疗可提高免疫治疗后寡进展的非小细胞肺癌患者的生存率：一项队列研究》的手稿
JTO Clin Res Rep. 2024 Nov 17;6(2):100767. doi: 10.1016/j.jtocrr.2024.100767. eCollection 2025 Feb.
9
Outcomes of surgery and subsequent therapy for central nervous system oligoprogression in EGFR-mutated NSCLC patients.表皮生长因子受体突变型非小细胞肺癌患者中枢神经系统寡进展的手术和后续治疗结果。
World J Surg Oncol. 2023 Nov 25;21(1):368. doi: 10.1186/s12957-023-03248-7.
10
Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC.转移性非小细胞肺癌免疫治疗失败后基于不同寡进展模式的治疗策略
Ther Adv Med Oncol. 2023 Mar 4;15:17588359231156387. doi: 10.1177/17588359231156387. eCollection 2023.

引用本文的文献

1
A Response Letter to Kosaka et al. Regarding Manuscript Titled: "Radiotherapy Improves Survival in Non-Small Cell Lung Cancer Following Oligoprogression on Immunotherapy: A Cohort Study".致小坂等人的回复信，关于题为《放射治疗可提高免疫治疗后寡进展的非小细胞肺癌患者的生存率：一项队列研究》的手稿
JTO Clin Res Rep. 2024 Nov 17;6(2):100767. doi: 10.1016/j.jtocrr.2024.100767. eCollection 2025 Feb.

本文引用的文献

1
Radiotherapy Improves Survival in NSCLC After Oligoprogression on Immunotherapy: A Cohort Study.放射治疗可提高免疫治疗后寡进展的非小细胞肺癌患者的生存率：一项队列研究。
JTO Clin Res Rep. 2024 May 30;5(10):100695. doi: 10.1016/j.jtocrr.2024.100695. eCollection 2024 Oct.
2
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study.标准治疗系统疗法联合或不联合立体定向体部放疗治疗寡进展性乳腺癌或非小细胞肺癌患者（放疗阻断寡进展[CURB]研究）：一项开放标签、随机、对照、2 期研究。
Lancet. 2024 Jan 13;403(10422):171-182. doi: 10.1016/S0140-6736(23)01857-3. Epub 2023 Dec 14.
3
Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial.在晚期实体瘤患者中，联合使用检查点抑制剂和立体定向体部放疗：CHEERS 阶段 2 随机临床试验。
JAMA Oncol. 2023 Sep 1;9(9):1205-1213. doi: 10.1001/jamaoncol.2023.2132.
4
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial.立体定向体部放疗后帕博利珠单抗与单纯帕博利珠单抗治疗晚期非小细胞肺癌患者肿瘤反应的效果：PEMBRO-RT 2期随机临床试验结果
JAMA Oncol. 2019 Sep 1;5(9):1276-1282. doi: 10.1001/jamaoncol.2019.1478.